Abstract:The use of CsA has evolved considerably in concept and practice since the First International Congress on this drug in 1983. CsA is now increasingly used as a component of a multiagent protocol, rather than as a single, potent agent, with adjunctive therapy selected to optimize induction or maintenance immunosuppression. Novel clinical developments include the prophylactic use of the MoAb OKT3 as an alternative to polyclonal ALG, and the coadministration of bromocriptine to inhibit prolactin-dependent immune augmentation. Other combinations with site-selective pharmacologic agents are now under investigation in vitro or in vivo to improve both the selectivity and potency of immunosuppression while reducing further the toxicity and cost of CsA. With the introduction of MoAb to CsA, rapid and specific measurement of the parent molecule will now become widely possible. Because of its simplicity and rapidity, this technique may well replace HPLC for routine monitoring, although the latter will remain indispensable in a research setting for measurement of individual metabolites. Specific measurement of the parent molecule is clearly important in heart or liver transplantation when hepatic metabolism is frequently grossly disturbed. There is less evidence that this will prove of value in renal transplantation, however, and it remains possible that by virtue of the biologic effect of certain metabolites, a more broadly crossreactive polyclonal assay is equal or superior in this setting. In this regard, the fluorescence polarization immunoassay is particularly attractive as a clinical monitoring system. It is simple, accurate, and cost-effective, and by virtue of its automation and speed, particularly adapted to outpatient monitoring. The planned introduction of new kits allowing measurement by monoclonal or polyclonal antibody in either serum or whole blood will make this a versatile system for the measurement of CsA.

The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation

The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis.

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Monitoring of Nuclear Factor of Activated T-cell-regulated Gene Expression in De Novo and Long-Term Liver Transplant Recipients Treated with Cyclosporine A.

The importance of early cyclosporine levels in pediatric kidney transplantation

Cyclosporine blood concentration in 553 cases allogeneic hematopoietic stem cell transplant recipients

Optimizing cyclosporine therapy: dose, levels, and monitoring

Evaluation of Factors Related to Blood Concentration of Cyclosporine A in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Linear correlation of C0 with C2 of plasma concentrations of cyclosporin A in prediction of early clinical outcomes of recipients after renal transplantation

Association of CYP3A Polymorphisms with the Pharmacokinetics of Cyclosporine A in Early Post-Renal Transplant Recipients in China.

Reaching the Cyclosporine a Level Target Slowly in Four Weeks Correlates with Better Prognosis for Chinese Patients after Allogeneic Haematopoietic Cell Transplantation

Time-dependent Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective

Efficacy and side‐effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients *

Population Pharmacokinetics of Ciclosporin in Allogeneic Hematopoietic Stem Cell Transplant Recipients: C-reactive Protein As a Novel Covariate for Clearance

Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients

Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion

Optimal Sampling Time-Point for Cyclosporin A Concentration Monitoring in Heart Transplant Recipients.

Monitoring of Ex Vivo Cyclosporin a Activity in Healthy Volunteers Using T Cell Function Assays in Relation to Whole Blood and Cellular Pharmacokinetics

Predictors and outcomes of dose reduction of methotrexate and cyclosporin graft-versus-host disease prophylaxis following allogeneic haemopoietic cell transplantation

Population Pharmacokinetic Study Of Cyclosporine In Hematopoietic Stem Cell Transplant Recipients

A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies.